Foundation tier · Weight Management
Semaglutide for Weight Management
A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.
Medical Disclaimer
Why Semaglutide for Weight Management
Role in Protocol
GLP-1 receptor agonist for weight management
Evidence Note
FDA-approved for chronic weight management. The STEP clinical trial program demonstrated average weight loss of 15-17% of body weight over 68 weeks in non-diabetic adults. The most extensively studied GLP-1 RA for obesity.
Literature Dosing
0.25-2.4 mg weekly SC -- STEP trial titration schedule
Dosing Context
Weight Loss (Wegovy)
Dose
0.25–2.4 mg
Frequency
weekly
Type 2 Diabetes (Ozempic)
Dose
0.5–2 mg
Frequency
weekly
Often Used Alongside
Key Safety Notes
Personal or family history of medullary thyroid carcinoma (MTC)
GLP-1 agonists caused thyroid C-cell tumours in rodents. Contraindicated if personal or family history of MTC.
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
MEN 2 predisposes to medullary thyroid carcinoma.
History of pancreatitis
GLP-1 agonists associated with acute pancreatitis in post-marketing reports. Use with extreme caution.
Full Semaglutide Profile →
Full Weight Management Protocol →